Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).
Conferences
McConkey, DJ; Choi, W; Halabi, S; Luo, B; Al-Ahmadie, HA; Rosenberg, JE; Mountain, J; Regazzi, AM; Fong, M; Iyer, G; Van Allen, EM; Mouw, KW ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
McConkey, D. J., Choi, W., Halabi, S., Luo, B., Al-Ahmadie, H. A., Rosenberg, J. E., … Morris, M. J. (2022). Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
McConkey, David James, Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat A. Al-Ahmadie, Jonathan E. Rosenberg, Jack Mountain, et al. “Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
McConkey DJ, Choi W, Halabi S, Luo B, Al-Ahmadie HA, Rosenberg JE, et al. Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
McConkey, David James, et al. “Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
McConkey DJ, Choi W, Halabi S, Luo B, Al-Ahmadie HA, Rosenberg JE, Mountain J, Regazzi AM, Fong M, Iyer G, Van Allen EM, Mouw KW, Wen Y, McCart L, Ballman KV, Beltran H, Morris MJ. Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P). JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis